{
    "ticker": "NRSN",
    "name": "NeuroSense Therapeutics Ltd.",
    "description": "NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of innovative therapies for neurodegenerative diseases, primarily Amyotrophic Lateral Sclerosis (ALS) and other related conditions. Founded in 2016, the company is dedicated to addressing the unmet medical needs of patients suffering from these debilitating disorders. NeuroSense's lead product candidate, PrimeC, is a combination therapy aimed at slow disease progression and improving the quality of life for ALS patients. The therapy leverages a unique mechanism of action that targets multiple pathways involved in neuronal degeneration. NeuroSense is committed to rigorous scientific research and has engaged in extensive preclinical and clinical studies to validate the efficacy and safety of its treatments. The company's mission is to provide hope and innovative solutions for patients and families affected by neurodegenerative diseases, paving the way for groundbreaking advancements in treatment methodologies. With a strong pipeline and a dedicated team of scientists and professionals, NeuroSense is poised to make a significant impact in the field of neurology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Herzliya, Israel",
    "founded": "2016",
    "website": "https://www.neurosensetx.com",
    "ceo": "Manuel Asher",
    "social_media": {
        "twitter": "https://twitter.com/NeuroSenseTx",
        "linkedin": "https://www.linkedin.com/company/neurosense-therapeutics/"
    },
    "investor_relations": "https://www.neurosensetx.com/investors",
    "key_executives": [
        {
            "name": "Manuel Asher",
            "position": "CEO"
        },
        {
            "name": "Elias K. Kouris",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PrimeC"
            ]
        }
    ],
    "seo": {
        "meta_title": "NeuroSense Therapeutics Ltd. | Innovative Neurodegenerative Disease Therapies",
        "meta_description": "Explore NeuroSense Therapeutics Ltd., a biotechnology company developing innovative therapies for ALS and other neurodegenerative diseases. Learn about their mission and lead product candidate, PrimeC.",
        "keywords": [
            "NeuroSense",
            "ALS",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "PrimeC",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What is NeuroSense Therapeutics focused on?",
            "answer": "NeuroSense Therapeutics is focused on developing therapies for neurodegenerative diseases, particularly ALS."
        },
        {
            "question": "What is PrimeC?",
            "answer": "PrimeC is NeuroSense's lead product candidate aimed at treating ALS by targeting multiple pathways of neuronal degeneration."
        },
        {
            "question": "When was NeuroSense founded?",
            "answer": "NeuroSense was founded in 2016."
        },
        {
            "question": "Where is NeuroSense headquartered?",
            "answer": "NeuroSense is headquartered in Herzliya, Israel."
        }
    ],
    "competitors": [
        "SRNE",
        "AVXL",
        "IONS",
        "CRMD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}